One-month atogepant treatment induces rapid changes in delta-band functional connectivity in migraine: an HD-EEG study
Abstract Background Atogepant is a novel oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the preventive treatment of migraine. While its peripheral mechanisms are well characterized, little is known about its potential effects on central functional brain networks. This s...
Saved in:
| Main Authors: | Matteo Conti, Silvio Bagetta, Federico Carparelli, Valerio Ferrari, Vittoria Carla D’Agostino, Fabio Placidi, Alessandro Stefani, Nicola Biagio Mercuri, Maria Albanese |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-07-01
|
| Series: | The Journal of Headache and Pain |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s10194-025-02115-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Atogepant for migraine prevention: a meta-analysis of safety and efficacy in adults
by: Adarsh Raja, et al.
Published: (2024-09-01) -
Corrigendum: Atogepant for migraine prevention: a meta-analysis of safety and efficacy in adults
by: Adarsh Raja, et al.
Published: (2025-04-01) -
“The efficacy and safety of Atogepant for migraine prophylaxis: a systematic review and meta-analysis of randomized controlled trials”
by: Ayesha Shaukat, et al.
Published: (2025-08-01) -
GIANT: a prospective, multicenter, real-world study on the effectiveness, safety, and tolerability of atogepant in migraine patients with multiple therapeutic failures
by: Piero Barbanti, et al.
Published: (2025-05-01) -
Clinical Pharmacokinetics of Atogepant in Healthy Japanese and White Adults
by: Ramesh R. Boinpally, et al.
Published: (2025-01-01)